Literature DB >> 32652488

Medicinal applications of cannabis/cannabinoids.

Irene Braithwaite1, Chiranth Bhagavan2, Marjan Doppen1, Stacey Kung1, Karen Oldfield3, Giles Newton-Howes4.   

Abstract

Regulatory approvals for Epidiolex (purified cannabidiol) in the treatment of childhood drug resistant epilepsy have set a precedent for the use of cannabinoids as a prescribed medicine. Two common reasons cited for the use and prescription of cannabis-based products are pain and insomnia. Unlike drug resistant epilepsy, the level of evidence of efficacy in pain is poorly developed. The lowest quality trials with the greatest methodological shortcomings suggest some benefit, a level of evidence that is inconsistent with widespread prescribing. The evidence in insomnia is scant. Ongoing trial development and critical review of the literature should not be overshadowed by increasing permissiveness towards cannabis use and anecdotal reports of efficacy.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32652488     DOI: 10.1016/j.copsyc.2020.06.002

Source DB:  PubMed          Journal:  Curr Opin Psychol        ISSN: 2352-250X


  2 in total

1.  Synthesis of sulfur karrikin bioisosteres as potential neuroprotectives.

Authors:  Martin Pošta; Václav Zima; Lenka Poštová Slavětínská; Marika Matoušová; Petr Beier
Journal:  Beilstein J Org Chem       Date:  2022-05-16       Impact factor: 2.544

2.  [Characterization of the problem of the therapeutic use of Cannabis Oil in Córdoba, Argentina].

Authors:  Pablo Gabriel Manzo; Sandra Martín; Sonia Uema; Germán Charles; Felipe Montero Bruni; Susana Núñez Montoya; María Eugenia Bertotto; Martín Eynard; Pedro Armando; Carolina Bustos Fierro
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2022-06-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.